## Another new application of heparin in COVID-19: more than anticoagulation and antiviral

Xianqiang Yu 💿

Medical School, Southeast University–Dingjiaqiao Campus, Nanjing, Jiangsu, China

## Correspondence to

Dr Xianqiang Yu, Medical School, Southeast University–Dingjiaqiao Campus, Nanjing, Jiangsu 210009, China; yuxianqiang302@126.com

Accepted 26 April 2021 Published Online First 10 June 2021



© American Federation for Medical Research 2021. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Yu X.*J Investig Med* 2021;**69**:1258.

Dear Editor,

We read with great interest an article in your journal about the relationship between heparin dose and anticoagulation effect of COVID-19 infection.<sup>1</sup> As the pandemic continues to spread and challenge, it is particularly important to standardize treatment protocols for COVID-19 anticoagulation. To the best of our knowledge, heparin-binding protein (HBP) has important clinical value as an early predictor of COVID-19 and its combination with heparin plays a key role in anticoagulant therapy.<sup>2</sup> In particular, the latest reports have unprecedentedly confirmed the anti-inflammatory mechanism of heparin in sepsis. From this perspective, heparin may play a double-edged sword effect in the antiinflammatory and anticoagulant effects of severe COVID-19.

It is reported that heparin inhibited HMGB1lipopolysaccharide interactions and prevented macrophage heparinase from degrading glycocalyx.<sup>3</sup> HMGB1 is a well-studied component of the damage-associated molecular pattern family. As a key potential therapeutic target in the occurrence and development of sepsis, it has always been the target of drug exploration. It is well known that heparin is a pluripotent drug for clinical favor, including anticoagulant, lipidlowering, anti-inflammatory, and so on. But to be clear, little is known about the mechanism by which heparin exacts its anti-inflammatory effects. We also noted that even if the anticoagulant part of heparin was removed, it could also play a significant anti-inflammatory effect in sepsis through the HMGB1 pathway. In other words, modified heparin can be used in inflammatory diseases without concern for its classical pharmacological side effects. Severe COVID-19 is often faced with a combination of severe inflammation and coagulation disorders. In particular, elevated HBP levels in patients with severe COVID-19 provide the possibility of carrying exogenous heparin. Therefore, from this point of view, heparin has multiple clinical values of anticoagulation and anti-inflammatory in the treatment of severe COVID-19. We have noted that there are currently a series of

randomized controlled trials of heparin in the treatment of COVID-19 anticoagulants. Therefore, the next focus should be to consider which patients with COVID-19 will benefit from heparin treatment, which will not, and which may even be impaired. With this in mind, the appropriate range of heparin in the treatment of patients with COVID-19 and the balance of its anticoagulant and anti-inflammatory doses are urgently needed to be clarified.

As the pandemic continues to spread and brings uncertain risks, targeted intervention drugs for severe COVID-19 are of far-reaching significance. In particular, heparin, as a potentially effective anti-inflammatory agent in severe patients, combined with its own anticoagulant effect may play a significant role in the treatment of severe COVID-19. The clarity of the anti-inflammatory mechanism of heparin through HMGB1 pathway gives us sufficient confidence in its potential anti-inflammatory value in patients with severe COVID-19. After all, there is reason to be optimistic about heparin as a new trial for an old drug.

**Contributors** XY completed the design and writing of the article and all the relevant contents of the manuscript.

**Funding** This study was funded by Scholarship of Southeast University (No 189351).

Competing interests None declared.

Patient consent for publication Not required.

**Provenance and peer review** Not commissioned; internally peer reviewed.

## ORCID iD

Xianqiang Yu http://orcid.org/0000-0001-7879-9826

## REFERENCES

- Carallo C, Pugliese F, Vettorato E, et al. Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia. J Investig Med 2021;69:884–7.
- 2 Saridaki M, Metallidis S, Grigoropoulou S, *et al.* Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19). *Eur J Clin Microbiol Infect Dis* 2021. doi:10.1007/s10096-020-04145-7. [Epub ahead of print: 29 Jan 2021].
- 3 Tang Y, Wang X, Li Z, *et al*. Heparin prevents caspase-11dependent septic lethality independent of anticoagulant properties. *Immunity* 2021;54:454–67.